HLS Therapeutics Inc
TSX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PW Medtech Group Ltd
HKEX:1358
|
CN |
HLS Therapeutics Inc
Total Current Assets
HLS Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
HLS Therapeutics Inc
TSX:HLS
|
Total Current Assets
$29.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
1%
|
|
|
M
|
Manitex Capital Inc
XTSX:MNX
|
Total Current Assets
CA$432.7k
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-25%
|
|
|
G
|
Greenrise Global Brands Inc
CNSX:XCX
|
Total Current Assets
€1.3k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
-38%
|
|
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
See Also
What is HLS Therapeutics Inc's Total Current Assets?
Total Current Assets
29.1m
USD
Based on the financial report for Dec 31, 2025, HLS Therapeutics Inc's Total Current Assets amounts to 29.1m USD.
What is HLS Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
1%
Over the last year, the Total Current Assets growth was -18%. The average annual Total Current Assets growth rates for HLS Therapeutics Inc have been -13% over the past three years , -9% over the past five years , and 1% over the past ten years .
